Reply  by Eldrup, Nikolaj et al.
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September 2012898 Letters to the Editorunderwent open AAA repair and 44,376 age-matched and sex-
matched controls with up to 20 years of follow-up. The large
number of patients and the length of follow-up, as well as the
validity of the registries used in the study, guarantee the soundness
of the conclusion that AAA patients have a high risk of atheroscle-
rotic events and death.
However, as the authors rightfully remark, the data are limited
because the status of comorbidities was unknown. Whereas an
AAA patient is more likely to have a heavier atherosclerotic burden
than an age-matched and sex-matched control, this is not true for
every single AAA patient. Individualization of the risk is important
and may not be very difficult because there are several easy and
reliable tools to do so, including the ankle-brachial index (ABI)
and carotid ultrasound imaging.
In a study performed 10 years ago, we showed that the
presence of carotid stenosis 50% in patients undergoing elective
open AAA repair was an independent predictor of long-term death
from cardiovascular causes, associated with a 3.6-times increased
risk, whereas the presence of echolucent plaques increased the risk
by 3.8 times.2 An ABI 0.9 was also an independent predictor of
fatal cardiovascular events, associated with a 2.8-times increased
risk.
On the basis of these observations, we suggested that AAA
may be divided into two pathologic entities: one with AAA as a
local manifestation and one with AAA as part of generalized
atherosclerosis. The long-term course differs in these two
groups: AAA patients with substantial atherosclerosis are at
increased risk of cardiovascular events, whereas it is doubtful
whether AAA patients without other evidence of atherosclerosis
are at increased risk compared with age-matched and sex-
matched controls.
Although the best model that adequately fits the data is
sometimes cumbersome, relative risk computation in means of
estimating hazards ratios from proportional hazard models should
initially account for possible confounders in order to sufficiently
warrant adjustment for them in the analysis.3 In the study by
Eldrup et al,1 unadjusted hazard ratios might have led into misin-
terpretation of the results, because patients operated on for AAA
were not matched for known atherosclerotic factors to the general
population, with the exception of previous myocardial infarction
and stroke. Moreover, the inclusion of patients with advanced
atherosclerotic disease, such as the 351 patients operated on for
both peripheral occlusive disease and AAA, may destruct model
fitness and deteriorate the clinical appropriateness of the final
results.
Pooling data may be a feasible strategy to increase the size of
the effect estimate. However, misestimating might negatively af-
fect clinical decision making or policy development. Subgroup
analyses can give more unbiased estimates for specific populations
and might eventually provide clinicians more insight toward better
treatment of patients.
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Thank you for the insightful response to our article. We fully
gree that the atherosclerotic burden in patients with aortic aneu-
ysm disease is probably not equal. Accordingly, we believe that
neurysm disease is a systemic tissue disorder rather than an ath-
rosclerotic manifestation.1 The two diseases do, however, share
any common risk factors, which perhaps explains the coincident
anifestation. It is important to note, however, that no study to
ate has proven that primary prevention in patients with an asymp-
omatic reduced ankle-brachial index will benefit from aspirin.2 It
s also becoming more apparent that in patients with asymptomatic
arotid plaques, the risk of major vascular events has been signifi-
antly reduced after the introduction of antithrombotics, statins,
nd increased antihypertensive medical treatment.3
In substance, we agree that the presence of a reduced ankle-
rachial index or a carotid plaque is associated with a higher
ardiovascular risk profile. However, no studies have tested
hether treatment in patients with abdominal aortic disease is not
eneficial in patients without these two disease markers. Recogniz-
ng that even after inclusion of the ankle-brachial index in risk
tratification models for otherwise healthy people, the discrimina-
ion only increases from 60% to 65% in men,4 with the conse-
uence of then incorrectly holding back prophylactic treatment in
p to 35% of the patients stratified.
This is also suggested in our data, where only marginal
hanges in risk of stroke, myocardial infarct, or all-cause mortality
re evidenced if all patients with previous stroke or myocardial
nfarct are taken out of the analysis.
Finally, we agree that the inclusion of the 356 patients treated for
eripheral occlusive disease and aneurysm at the same time could
otentially have biased the conclusions. With 2000 myocardial
nfarcts and 1000 strokes, however, it is unlikely that these 356
atients all should have an event and thereby render a false conclusion.
Until better models exist, we will still argue that all patients
ith an abdominal aortic aneurysm should receive treatment with
oth antithrombotics and statins.
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Regarding “Cost implications of more widespread
carotid artery stenting consistent with the American
College of Cardiology/American Heart Association
guideline”
The recent article by Paraskevas et al1 brings important atten-
tion to the cost implications of more widespread replacement of
carotid endarterectomy (CEA) with carotid artery stenting (CAS).
They reported charges instead of costs, and charges are difficult to
interpret in theMedicare population because cost and payment are
not the same as charges. Charges are an indicator of what the
hospital would like to be paid, but in the United States, this does
not necessarily predict what the hospital will be paid. Also, charges
are proportional to cost but are not the same as cost.
Almost simultaneous to the publishing of that article, we
published a report comparing costs and payments for carotid
endarterectomy (CEA) and carotid stenting (CAS) in asymptom-
atic Medicare patients.2 We noted that the cost of CAS was about
$5000 higher than the cost for CEA,2 which is more tangible than
a $12,000 difference in charges. The charges and cost are indeed
Dr Cloft is the Primary Investigator at an enrolling site for the SAPPHIREh
(Stenting and Angioplasty with Protection in Patients and HIghRisk for
Endarterectomy) registry sponsored by Cordis Endovascular.oth higher, but then we need to factor in the payments. The
ifference inDiagnosis-RelatedGroup payment for uncomplicated
ases is about $4000 higher for carotid stenting,2 so that is what
he government’s incremental cost would be for each Medicare
atient converted to CAS.
Because each hospital tends to lose $1300 on a CEA and
$3200 on a stent,2 the average net increase in loss to the hospitals
or each Medicare patient converted from CEA to CAS is $1900.
e can thus conclude that if an additional 50,000 patients per year
ere to be switched from CEA to CAS so that the percentages of
EA and CAS became similar (ie, 50% for CAS and 50% for CEA),
he hospitals would lose an additional $95 million each year,
espite Medicare making an additional $200 million in payments
o the hospitals. These facts further highlight the conclusion of
araskevas et al1 that diverting a large number of patients to
tenting has a huge economic impact.
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